Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis"
- PMID: 35175430
- DOI: 10.1007/s10549-022-06542-2
Comment on "Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis"
Comment on
-
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.Breast Cancer Res Treat. 2022 Jan;191(2):269-275. doi: 10.1007/s10549-021-06436-9. Epub 2021 Nov 3. Breast Cancer Res Treat. 2022. PMID: 34731351
References
-
- Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, Ruelle T, Pronzato P, Massarotti C, Franzoi MA, Lambertini M, Tagliamento M (2022) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat 191(2):269–275 - DOI
-
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535 - DOI
-
- Sun P, Wang Y, Chen Z (2019) Meta-analysis should be done in a normative manner. Aesthet Plast Surg 43(4):1128–1129 - DOI
Publication types
LinkOut - more resources
Full Text Sources